MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells by Lacunza, E et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
MUC1 oncogene amplification correlates with protein
overexpression in invasive breast carcinoma cells
Lacunza, E; Baudis, M; Colussi, A G; Segal-Eiras, A; Croce, M V; Abba, M C
Lacunza, E; Baudis, M; Colussi, A G; Segal-Eiras, A; Croce, M V; Abba, M C (2010). MUC1 oncogene
amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genetics and
Cytogenetics, 201(2):102-110.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Cancer Genetics and Cytogenetics 2010, 201(2):102-110.
Lacunza, E; Baudis, M; Colussi, A G; Segal-Eiras, A; Croce, M V; Abba, M C (2010). MUC1 oncogene
amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genetics and
Cytogenetics, 201(2):102-110.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Cancer Genetics and Cytogenetics 2010, 201(2):102-110.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 1 
MUC1 ONCOGENE AMPLIFICATION CORRELATES WITH PROTEIN 
OVER-EXPRESSION IN INVASIVE BREAST CARCINOMA CELLS 
 
Lacunza E 
a
, Baudis M 
b
, Colussi AG 
a
, Segal-Eiras A 
a
, Croce MV 
a
, Abba MC 
a,*
. 
 
a 
Centro de Investigaciones Inmunológicas Básicas y Aplicadas (CINIBA). Facultad de Ciencias Médicas. 
Universidad Nacional de La Plata, Argentina. 
b 
Institute of Molecular Biology, University of Zurich, Winterhurerstrasse 190, CH-8057, Zurich, 
Switzerland. 
 
* Corresponding author. Centro de Investigaciones Inmunológicas Básicas y Aplicadas (CINIBA), 
Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Calle 60 y 120, La Plata, CP:1900, 
Argentina. E-mail address: mcabba@conicet.org.ar (Abba MC).  
 
 
*Manuscript
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
ABSTRACT  
The MUC1 gene is aberrantly over-expressed in approximately 90% of human breast 
cancers. Several studies have shown that MUC1 over-expression is due to 
transcriptional regulatory events. However, the importance of gene amplification as a 
mechanism leading to the increase of MUC1 expression in breast cancer has been 
poorly characterized. The aim of this study was to evaluate the role of MUC1 gene 
amplification and protein expression in human breast cancer development. Using real-
time quantitative PCR (Q-PCR) and immunohistochemistry (IHC) methods, 89 breast 
tissue samples were analyzed for MUC1 gene amplification and protein expression. Q-
PCR analysis showed MUC1 genomic amplification and a positive association with the 
histopathological group in 12% (1 out of 8) of benign lesions and 38% (23 out of 60) of 
primary invasive breast carcinoma samples (p=0.004). Array-CGH meta-analysis of 886 
primary invasive breast carcinomas obtained from 22 studies showed MUC1 genomic 
gain in 43.7% (387 out of 886) of the samples. Moreover, we identified highly statistical 
significant association between MUC1 gene amplification and MUC1 protein 
expression assessed by IHC and western-blot (p<0.0001). In conclusion, this study 
demonstrated that MUC1 copy number increases from normal breast tissue to primary 
invasive breast carcinomas in correlation with MUC1 protein expression.  
 
Key Words: MUC1, protein expression, gene amplification, breast cancer. 
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1. INTRODUCTION 
DNA amplification is a common mechanism used by cancer cells to up-regulate the 
activity of critical genes associated with tumor development and progression [1, 2]. 
In breast cancer, a number of discrete amplicons have been identified, involving ERBB2 
(17q12), MYC (8q24), CCND1 (11q13), AIB1 (20q13) and FGFR (10q26) genes [3, 4, 
5, 6, 7]. The most common regions of increased DNA copy number in breast cancer as 
determined by Comparative Genomic Hybridization (CGH) include the chromosome 
arm 1q, where an unambiguous target gene has not been identified yet [8, 9]. Although 
regional genomic copy number amplifications frequently increase the expression of 
relevant oncogenes, they may also serve as an indicator of genomic instability [10]. As 
such, presence of one or several gene amplifications may have prognostic significance.  
MUC1 oncoprotein is aberrantly overexpressed in approximately 90% of human breast 
cancers [11, 12, 13], which has been associated with cell adhesion inhibition as well as 
increased metastatic and invasive potential of tumor cells [14]. This over-expression 
allows MUC1 to interact with members of the ERBB family of receptor tyrosine kinases 
[15]. In addition, the MUC1 cytoplasmic domain, which comprises the last 72-aa, also 
interacts with diverse effectors that have been linked to transformation, such as c-Src, β-
catenin, and IKβ /NF-KB [15, 16, 17].  
Several studies have shown that MUC1 over-expression is in part due to transcriptional 
regulatory events [18, 19, 20, 21]. Furthermore, MUC1 regulation has been also 
associated to epigenetic changes in cancer cells [22]. However, the importance of gene 
amplification as a mechanism leading to the increase of MUC1 expression in breast 
cancer has been poorly characterized. In an early study, Bièche and Liderau (1997) have 
postulated a concordance between MUC1 mRNA expression and gene dosage in breast 
carcinomas [23]. Similar observations were further reported affecting ovary, thyroid and 
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gastric carcinomas [24, 25, 26]. Interestingly, a recent array-CGH study coupled to 
genome-wide transcriptome map showed a cluster of genes, located at 1q21.3-1q22, 
exhibiting the strongest association between copy number and gene expression in 
primary breast carcinomas [27]. In addition, in silico analysis of the transcriptomic 
profile, based on our previously published SAGE (Serial Analysis of Gene Expression) 
data sets [28, 29], showed that MUC1 is the most frequently up-regulated gene at 
1q21.3-1q22 chromosomal region in primary invasive breast carcinomas. Thus, the 
possible association between MUC1 expression and gene amplification could reveal 
novel information about MUC1 as a predictive breast cancer gene. The aim of this study 
was to evaluate the role of MUC1 gene amplification and protein expression in human 
breast cancer progression. 
 
2. MATERIAL AND METHODS 
2.1 Tissue samples and cell lines 
A total of 83 formalin-fixed paraffin-embedded breast tissue specimens were obtained 
from different hospitals associated to the National University of La Plata-Argentina. 
They included 15 normal tissues from individuals who underwent cosmetic surgery, 8 
benign lesions and 60 primary invasive ductal carcinomas (IDCA, ICD-O 3 8500/3). 
Since the hypothetical multistep model for breast carcinogenesis suggests that invasive 
carcinoma arises via a series of intermediate hyperplasic lesions to in situ and invasive 
carcinoma, benign lesions included in this study were all usual epithelial hyperplasia 
(UEH). Stage at time of diagnosis was based on the TNM classification. The breast 
cancer cell lines MCF7, T47D, ZR75-1 and the MRC5 normal lung fibroblast cells were 
also included. The study was performed with respect to the ethical standards of the 1975 
Declaration of Helsinki, as revised in 1983. 
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2.2 Cell culture  
The estrogen-dependent breast cancer cell lines MCF7, T47D and ZR75-1 were grown 
in RPMI-1640 medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% (v/v) 
FBS (Bioser, Buenos Aires, Argentina), 10 IU/ml penicillin G, and 10 μg/ml 
streptomycin. The human diploid fibroblast cell strain MRC5 was grown in Minimal 
Essential Medium (Gibco, Gaithersburg, MD, USA), supplemented with non-essential 
amino acids and 0.1% sodium pyruvate (Gibco, Gaithersburg, MD, USA). Cells 
cultures were harvested by rinsing the monolayer with cold lysis buffer; the cell 
suspension was centrifuged and the pellet recovered before tissue digestion (see below). 
 
2.3 DNA extraction and purification 
Paraffin embedded samples from breast tissues were processed by routine techniques 
for histological analysis. Briefly, four 10 µm paraffin embedded tissue from each biopsy 
were used for DNA extraction. Tissue digestion was performed by incubating in 
extraction buffer (1M Tris-HCl, ph 8; 1mM EDTA; 1% Tritón; 0.5% Tween) with 
proteinase K at 56° C overnight. Finally, DNA from tissue samples and cell lines was 
purified by phenol-chloroform-isoamylalcohol method (25:24:1) followed by ethanol 
precipitation as was previously described [30]. The DNA was resuspended in distilled 
water. DNA concentration was measured on the Nanodrop
®
 spectrophotometer and 
adjusted to 30ng/µl. 
 
2.4 Real-Time Quantitative PCR analysis (Q-PCR) 
DNA Q-PCR was done using the PerfeCta SYBR Green SuperMix (Quanta 
Biosciences) and the Stratagene MX30005P Real-Time PCR System. The efficiency-
corrected comparative ∆∆Ct method was applied, and the ∆Ct of a human normal diploid 
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lung fibroblast cell strain (MRC5 cells, not immortal), run in parallel with each assay, 
was used for calibration to get the relative quantification for each tumor or cell line 
sample versus a normal chr1 gene copy number control. In this experiment, MUC1 and 
PUM1 (Pumilio homolog 1) were used as the target and normalizing reference genes, 
respectively. MUC1 gene maps in the chromosome region 1q21.3-q22, whereas PUM1 
is located at the chromosome region 1p35.2. The MUC1 amplicon (86 bp) (Figure 1A) 
does not include the tandem repeat region present within the MUC1 gene and PUM1 
gene has been well established as a reference control in breast cancer samples [31]. 
The PCR reactions were performed using 12.5 µl of the SuperMix (Quanta 
Biosciences), 5 µl of DNA templates and 1 µl of MUC1 (forward 5’-
gctgctcctcacagtgctt-3’ and reverse 5’-cacagaaagaccacgaaga-3’) or PUM1 (forward 5’-
tccatcttcatcctaccgc-3’ and reverse 5’-aagggacaatctgctcgttag-3’) primers at 10 
picomoles/µl. The reactions were cycled as follows: 1 cycle of 45°C for 5’, 1 cycle of 
95°C for 3’ followed by 40 cycles of 95°C for 1’, 57°C for 30’’ and 95°C for 30’’. PCR 
amplification was followed by melting curve analysis to assure the presence of a single 
PCR product (Figure 1B). Samples were considered to be affected by genomic 
amplification for MUC1 gene when the relative quantitative values were greater than 
+3SD (99%CI; p<0.01) with respect to the values observed for the normal breast 
samples. All samples were analyzed in triplicate to confirm the obtained values. 
 
2.5 Immunohistochemistry analysis (IHC) 
IHC was performed according to standard procedures as previously reported [32]. 
Briefly, sections of 4 µm thick were cut from block paraffin tissue samples, de-waxed 
and rehydrated using xylene and ethanol, respectively. Endogenous peroxidase activity 
was blocked by treatment with 0.3% H2O2 (MERCK, Germany) in methanol. Then, 
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slides were incubated in 10% horse normal serum in 1% bovine serum albumin (BSA) 
(Sigma, USA)–PBS to eliminate background reaction, and antigenic recuperation was 
performed by heating at 100 °C in 10mM sodium citrate buffer pH6.0. Mouse 
antihuman polyclonal antibody against MUC1 (CT33) was used at a dilution of 1:500. 
This antibody is directed against the last 72 amino acids of the MUC1 cytoplasmic 
domain. Samples were incubated overnight with the primary Ab at 4 °C, whereas 
negative controls were incubated with PBS under the same conditions. After incubation 
with secondary peroxidase labeled anti-armenian hamster Ig (1:150; Dako, Denmark), 
reaction was developed with 3-30-diaminobencidine and 0.03% H2O2 in PBS. Finally, 
sections were counterstained with hematoxylin (Sigma, USA), dehydrated and covered 
with mounting media. Samples were evaluated under light microscope. A reaction was 
considered positive when more than 5% of the cells were stained. The patterns of 
reaction were: L = linear membrane, C = cytoplasmic and M = mixed, linear and 
cytoplasmic; nuclear staining was also recorded. Staining intensity was scored in a 
semi-quantitative manner and was graded as negative (-), low (+), moderate (++) and 
strong (+++). 
 
2.6 Western-blot analysis (WB) 
Homogenates from breast tissue samples were filtered through a mesh and centrifuged 
at 1500 g, 4 °C for 15 min; the resulting supernatants were subjected to SDS-PAGE and 
WB analysis. Electrophoretic separation of proteins was performed with discontinuous 
4% stacking-10% resolving polyacrylamide gels under reductive conditions employing 
a miniVE Vertical Electrophoresis System (Amersham Biosciences Corp.). Gels were 
transferred to nitrocellulose membranes, which were blocked with 3% dry milk in 
PBS/Tween-20 (0.05%) at 4-8°C for 3-h and then washed in PBS/Tween-20 (0.05%). 
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Membranes were incubated with CT33 Ab (1:1000 in 1% milk/PBS Tween 20) at 4°C 
overnight. After washing, membranes were incubated with the horseradish peroxidase 
(HRP)-conjugated anti-armenian hamster Ig (Dako, Denmark) (1:1000) at room 
temperature for 1-h. Finally, reaction was developed with diaminobenzidine (Sigma, 
USA). As an internal control, beta-actin WB was done by incubating membranes with 
AC15 AMo (1:5000 in 1% milk/PBS Tween 20). WB bands intensity analysis was 
performed by using the Scion Image Software. 
 
2.7 Bioinformatics and statistical analysis. 
To perform the comparative analysis of the transcriptomic profiles in a set of normal 
and breast cancer samples, we combined 6 normal breast SAGE libraries -available in 
public databases (http://cgap.nci.nih.gov/cgap.html)- with 23 invasive breast cancer 
SAGE libraries previously reported by us [29]. To compare the 29 SAGE libraries, we 
utilized a modified t-test as was previously described [28]. This analysis allowed us to 
identify SAGE tags with significantly different expression levels between normal and 
invasive ductal carcinomas (p<0.01).  
To enable visualization and illustration of the 1q21-q23 chromosome region in MCF7, 
T47D and ZR75-1 breast cancer cell lines from Pollack's and Chin's array-CGH data [9, 
27], we used the VAMP software (Visualization and Analysis of array-CGH, 
transcriptome and other Molecular Profiles) (http://bioinfo-out.curie.fr/actudb) (33). 
The association between MUC1 gene amplification, protein over-expression and 
histological status of the samples was assessed by Fisher's exact test: the two way 
contingency tables were the result of defining the variables amplification status, which 
was codified as 0 to non amplified samples and 1 to amplified samples, and protein 
expression that was coded according to the grade of staining intensity obtained by IHC 
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 9 
as 0 (-), 1(+), 2(++) and 3(+++). To test the independence of variables, the basic 
significance level was fixed at p<0.05. In addition, ordinal-by-ordinal associations were 
assessed by Kendall's tau-b test. Data analysis was performed using the SPSS Statistics 
17.0 software package. 
As reference for overall frequency of DNA imbalances affecting the region 1q21.3-q22, 
comparative genomic hybridization (CGH) data of 886 primary IDCA cases (ICD-O 3 
8500/3) from the Progenetix database (http://www.progenetix.net) (34) was used.  
 
3. RESULTS 
We analyzed the global gene expression profile in a set of normal and breast cancer 
SAGE libraries (Serial Analysis of Gene Expression) previously published by us [28, 
29]. Interestingly, we identified the MUC1 gene among the most highly up-regulated 
group of transcripts in the primary invasive breast cancer SAGE libraries at 
transcriptomic level (see Figure 1 supplementary). Specifically, according to the in 
silico analysis of our SAGE database, MUC1 was detected as being the most frequently 
up-regulated gene located at 1q21.3-1q22 chromosomal region of invasive breast 
carcinomas . 
Microarray-based comparative genomic hybridization evidence (array-CGH) is 
available reporting the relative DNA copy number profile of the chromosome 1 in 
breast cancer cell lines [9, 27]. The VAMP resource [33] was employed for aCGH data 
analysis of chromosome region 1q21.3-q22 from MCF7, T47D and ZR75-1 breast 
cancer cell lines. In silico analysis of Pollack's and Chin's data [9, 27] identified a gain 
of chromosome regions 1q21.3-q22 including the MUC1 gene region in T47D cell line 
(Figure 2A). Next, we used a Q-PCR method for the interrogation of the presence or 
absence of MUC1 genomic amplification in these breast cancer cell lines. The 
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specificity of the MUC1/PUM1 gene products was verified through melting curve 
analysis after Q-PCR cycles, as well as gel electrophoresis (Figure 1). Amplicons of the 
expected size for MUC1 (89 bp) and PUM1 (92 bp) were confirmed in the normal 
diploid MRC5 cell strain (Figure 1A). In addition, melting curve analysis confirmed the 
specificity of primers, since we did not observe any deviation from the average melting 
curve profile in all DNA samples analyzed (Figure 1B). Q-PCR analysis showed MUC1 
gene amplification in T47D cell line, while no amplification was detected for the MCF7 
and ZR75-1 cancer cell lines, in agreement with the array-CGH data and validating the 
method (Figure 2B). 
To investigate whether MUC1 protein over-expression correlates with gene 
amplification in breast cancer development, we analyzed DNA obtained from 89 breast 
tissue samples. Samples were considered to be affected by MUC1 genomic 
amplification when the relative DNA copy number was greater than +3SD (99%CI; 
p<0.01) with respect to the values observed in normal specimens. According to these, 
MUC1 genomic amplification was detected in 12% (1 out of 8) of benign lesions and 
38% (23 out of 60) of primary invasive breast carcinoma samples (Figure 2C). The 
statistical analysis revealed a significant positive association between the 
histopathological group and MUC1 DNA copy number changes (p=0.004) (Figure 2). 
Moreover, to explore the frequency of DNA copy number gains/losses affecting the 
chromosome region 1q21.3-q22 in independent set of samples, we analyzed 
chromosomal and array CGH data of 886 individual IDC cases as collected in the 
Progenetix online database. In this data set, which did not include cell lines, a gain or 
genomic amplification involving the MUC1 locus on 1q22 (UCSC HG18 
chr1:153,424,924-153,429,324) could be found in 387 out of 886 cases (43.7%) (Figure 
3). To further investigate the relevance of MUC1 gene amplification over protein 
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expression in breast cancer progression, we studied 74 specimens by IHC from the 89 
samples previously analyzed by Q-PCR (Table 1). Since MUC1 protein is highly 
glycosylated and this could block or hamper binding of antibodies, we employed the 
well characterized polyclonal antibody CT33, developed against the MUC1 
unglycosylated cytoplasmic domain [32]. MUC1 protein expression was detected in all 
normal breast samples analyzed. As it was expected, the reaction was restricted to the 
apical membranes of epithelial cells, which displayed a weak or moderate MUC1 
immunostaining. However, in benign lesions a moderate to strong MUC1 expression 
was observed in approximately 87% of the analyzed cases (Table 1). Furthermore, the 
pattern of reaction varied from linear to mixed (linear/cytoplasmic). Among invasive 
ductal carcinomas, MUC1 protein was detected in 93% of the analyzed cases with a 
strong intensity of expression in approximately 72% of the samples (Table 1). 
Frequently, cytoplasmic staining was observed together with
 
a membrane reaction in a 
mixed pattern at equal intensity, although some samples showed a linear pattern. It is 
also important to note that MUC1 reaction comprised the entire cell in many carcinoma 
samples. More importantly, MUC1 protein expression analysis demonstrated a highly 
statistical significant association between MUC1 gene amplification and MUC1 over-
expression (p<0.0001) (Figure 4). In this sense, 23 out of 26 amplified samples 
displayed a high expression of MUC1 protein, whereas the remainder samples (3 out of 
26) showed moderate intensity of MUC1 protein expression (Table 1). Non-statistical 
significant association were detected between MUC1 protein expression / gene 
amplification and ERα status, histologic tumor grade and tumor stage (p=0.05). 
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4. DISCUSSION 
Breast cancer progresses as a result of the accumulation of genomic changes, which is 
thought to underlie the clonal evolution of cancer disease [35]. Moreover, in a 
significant subset of human breast cancers, as in other solid tumors, gene amplification 
is an important mechanism for oncogene activation during tumor progression [9].  
The MUC1 oncogene, located at the 1q21.3-q22 chromosomal region, is markedly 
overexpressed in breast cancer and has been associated with aggressive tumor behavior 
[14]. In this study, in silico analysis of previously published SAGE databases [28, 29] 
lead us to identify MUC1 gene as the most up-regulated transcript from the 1q21.3-q22 
chromosomal region in invasive breast carcinomas. Indeed, up-regulation of MUC1 
appears to be specifically associated with adenocarcinomas from various sources, which 
has been correlated with increased metastatic potential and poor prognosis [14, 25]. 
Many studies have revealed that the increase of MUC1 expression is related with 
transcriptional regulatory events or epigenetic changes [19, 18, 20, 22]. However, in an 
early study, Bièche and Liderau [23] found a concordance between the MUC1 DNA 
relative copy numbers and MUC1 mRNA expression levels in primary breast 
carcinomas, suggesting a gene dosage effect. Interestingly, in a wide variety of 
carcinoma types including ovary, papillary thyroid and gastric cancers, MUC1 
amplification and over-expression was also found [25, 24, 26]. These observations 
support a functional role of MUC1 as part of the frequent DNA copy number gains 
observed in a variety of epithelial neoplasias and possibly other malignancies [36]. 
In this study, we performed a Q-PCR and IHC analyses on malignant, benign and 
normal breast epithelial tissue samples and breast cancer cell lines, in order to determine 
whether gene amplification is a mechanism leading to MUC1 over-expression. Q-PCR 
has proven to be a very powerful tool to analyze gene copy variations in cancer [25, 37]. 
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By this method, we detected MUC1 gene amplification in 12% of benign lesions and 
38% of invasive breast carcinomas. We also found gene amplification in the T47D 
breast cancer cell line as was previously evidenced by array-CGH analysis. The results 
of our study show that MUC1 gene copy number increases in invasive breast samples 
and in the hyperplasic lesions, which means that this gene could have an early causal 
role in the breast cancer development.  
To determine whether MUC1 gene amplification status is also correlated with protein 
over-expression in breast tumors, we analyzed MUC1 protein expression by IHC in a 
set of 74 samples previously characterized for MUC1 DNA copy number. Previous 
studies have demonstrated that the MUC1 oncoprotein is overexpressed in breast cancer 
and other solid tumors [38, 39, 40]. The NH2 terminal mucin domain of MUC1 on 
normal breast epithelial cells carries numerous branched O-linked carbohydrates, which 
can block binding of antibodies directed against this region, whereas MUC1 molecules 
derived from carcinomas usually contain shorter non-branched glycans, allowing the 
access of the antibodies to their epitopes. For this reason, to avoid confusing results, we 
employed the CT33 polyclonal antibody [32]
 
developed against the unglycosylated last 
72 amino acids of the COOH terminal domain of MUC1. Although the degree of 
expression and cellular localization varied significantly between tumor and normal 
tissue and among tumor samples, we observed MUC1 over-expression in 62.5% of 
benign lesions and 72% of invasive breast carcinomas. In addition, in most carcinoma 
specimens the pattern of reaction was mixed or cytoplasmic, which confirms the lost of 
polarity of MUC1 compared with normal tissue samples. More importantly, the results 
obtained by IHC showed a significant correlation with MUC1 gene amplification status 
of the analyzed cases (p=0.0001). Although almost all amplified samples showed a 
strong MUC1 protein expression (23 out of 26 amplified samples), some breast 
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carcinomas showed over-expression of MUC1 in the absence of gene amplification, 
suggesting that the up-regulation of MUC1 expression in these samples would be 
mediated by another mechanism. Interestingly, array-CGH / DNA microarray evidence 
is available reporting amplification and over-expression of the chromosomal region 
1q21.3-q22 (the same region to which MUC1 maps) in breast cancer cell lines and 
primary breast carcinomas [27]. Moreover, a genome-wide transcriptome map revealed 
clusters of genes located at 1q21 exhibiting nonrandom increased expression in breast 
cancer cells [41]. 
 
5. CONCLUSION 
This study demonstrates that MUC1 protein over-expression correlates with gene 
amplification and that this mechanism could be evident in early stages of breast cancer 
development. The frequent regional copy number gains involving 1q21.3-q22 in breast 
carcinomas and a variety of other neoplasias may modulate tumor cell behavior acting 
through MUC1 as one of the (presumably multiple) oncogenetic target genes in this 
region. However, gene amplification would not be the only explanation for the MUC1 
over-expression at the protein level, suggesting that other molecular mechanisms, such 
as regulatory transcriptional events and epigenetic control would have effect alone or in 
concert with copy number alteration in deregulating MUC1 gene expression in breast 
cancer cells. 
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Table 1. MUC1 protein expression and gene amplification in breast tissue samples. 
Characteristics MUC1 protein expression    n (%) Cases 
Absent   Weak Moderate Strong  
MUC1 gene status      
Non amplified  5 (10%) 7 (15%) 9 (19%) 27 (56%) 48 
Amplified 0 (0%) 0 (0%)  3 (11%) 23 (89%) 26 
Histology      
Normal tissue 0 (0%) 2 (33%) 2 (33%) 2 (33%) 6 
Benign lesions (UEH) 1 (12%) 1 (12%) 1 (12%) 5 (63%) 8 
Invasive carcinomas 4 (7%) 4 (7%) 9 (15%) 43 (72%) 60 
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Figure Legends  
 
Figure 1. (A) PCR assay showing the MUC1 and PUM1 gene products in MRC5 cell 
line optimized at different concentration of DNA template. (B) Dissociation (Melting 
Curve) analysis plot showing a single homogeneous peak for MUC1 and PUM1 PCR 
products in MRC5 cell line, which confirms specific amplification. (C) Standard curves 
plot of PUM1 and MUC1 obtained with serial dilutions of MRC5 DNA. It shows the 
initial concentration against the Ct generated for each dilution as well as the efficiency 
of amplification.  
 
Figure 2. MUC1 gene amplification analyses in breast samples. (A) Visualization of 
1q21.3-q22 microarray-based CGH profile of MCF7, T47D and ZR75 breast cancer cell 
lines obtained from Pollack et al. and Chin et al. studies [9, 28]. Red lines indicate 
chromosomal regions of gain. These data suggest a region of genomic gain located at 
1q21.3-q22 involving the MUC1 gene. (B) Q-PCR assay showed MUC1 gene 
amplification in T47D breast cancer cell line in agreement with Pollack and Chin data. 
(C) MUC1 DNA copy number ratios of breast tissue samples. Differences between 
normal (n=15), benign (n=8) and invasive carcinomas (n=60) were detected (p<0.001).  
 
Figure 3. Frequency of regional genomic imbalances in 886 invasive ductal carcinomas 
(ICD-O -3 8500/3) as determined by chromosomal or array CGH. (A) Subset of 387 
cases (43.7%) showed genomic gains involving the MUC1 locus on 1q22 (arrow on 
chromosome 1 plot). The overview histogram shows the frequency plot for regional 
genomic gains (green, upwards) and losses (1q22 = 100% for gains). In (B), the 
corresponding plot for the 499 cases negative for 1q22 gains is shown. With the whole 
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or near-complete 1q gains removed, an additional distal gain hot-spot becomes apparent 
at band 1q32. While the distribution pattern of genomic gains and losses is of a similar 
shape, the overall lower aberration frequency in B may be due to the selection bias  
introduced through exclusion of 1q22 gains. 
 
Figure 4. MUC1 gene amplification and protein expression analyses in breast samples. 
(A) MUC1 real-time quantitative PCR of eleven breast samples (5 IDCA, 1 benign 
lesion, and 5 normal breast epithelia). MUC1 plot shows all the IDCA samples and the 
benign lesion (arrows 3 and 2, respectively) amplified respect to the normal samples 
(arrow 1). (B) IHC results obtained with the CT33 Ab. 1, 2 and 3 are the same samples 
indicated in the MUC1 amplification plot. 1. Normal breast epithelial tissue, a moderate 
reaction is observed at the apical membranes (linear pattern) of the epithelial cells, 
indicated with an arrowhead 2. Benign lesion (UEH), a strong reaction with a mixed 
pattern is clearly observed in the epithelial cells of ducts. 3. IDCA, a strong reaction is 
observed in the entire cell surface with a high percentage of reaction. (C) WB analysis 
the same samples. Compared with lane 1 (normal breast tissue), a more intense band is 
observed in lanes 2 and 3, corresponding to benign and carcinoma samples, 
respectively. 
 
Figure 1 supplementary. Bar charts of the 30 most commonly up-regulated genes in 
primary invasive breast carcinomas (IDCA) based on the Log2 ratio value of the mean 
expression levels between breast cancer and normal breast SAGE libraries. The 
corresponding chromosome regions of each gene are indicated inside the bars with 
white numbers. Arrows indicate those genes that map on 1q chromosome region. MUC1 
gene is highlighted in boldface. 
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